FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2925036534> ?p ?o ?g. }

• W2925036534 endingPage "73" @default.
• W2925036534 startingPage "67" @default.
• W2925036534 abstract "Background Standard dosing regimen of sunitinib for metastatic renal cell carcinoma consists of four weeks treatment followed by two weeks rest (intermittent dosing). Alternative regimens have been suggested, including continuous daily dosing (continuous dosing) and non-conventional dosing (non-conventional dosing: e.g. two weeks on/one week off, non-conventional dosing), to provide more individualized therapy with less toxicities. It is unclear whether non-standard sunitinib dosing affects survival outcomes. Patients Metastatic renal cell carcinoma patients treated with sunitinib between 1 July 2007 and 1 July 2011 at our institution. Methods Medical records and dispensing data were reviewed retrospectively to categorize sunitinib dosing as intermittent dosing, continuous dosing, or non-conventional dosing. Primary outcome was to compare overall survival associated with varying regimens, with secondary outcomes of progression-free survival and incidence of treatment discontinuation due to adverse effects. Results A total of 180 patients were identified. Most patients received intermittent dosing ( n = 120, 67%), followed by continuous dosing ( n = 32, 18%) and non-conventional dosing ( n = 28, 16%). Compared to intermittent dosing, continuous dosing was associated with similar overall survival (median 9 vs. 13 months, HR 0.67, 95% CI: 0.43–1.06, p = 0.088) while non-conventional dosing was associated with significantly longer overall survival (median 9 vs. 23 months, HR 0.55, 95% CI: 0.34–0.90, p = 0.016). Progression-free survival was significantly better for continuous dosing (median 4 vs. 9 months, HR 0.61, 95% CI: 0.40–0.94, p = 0.025) and non-conventional dosing (median 4 vs. 10 months, HR 0.61, 95% CI: 0.39–0.95, p = 0.03) when compared to intermittent dosing. Similar to prior sunitinib trials, a significant proportion of patients (20%) discontinued sunitinib therapy due to adverse effects. Conclusions Based on retrospective, real-world data, alternative sunitinib dosing regimens appear to be viable options for patients with metastatic renal cell carcinoma." @default.
• W2925036534 created "2019-04-01" @default.
• W2925036534 creator A5019396140 @default.
• W2925036534 creator A5039901519 @default.
• W2925036534 creator A5061726791 @default.
• W2925036534 creator A5087150696 @default.
• W2925036534 date "2019-03-25" @default.
• W2925036534 modified "2023-10-16" @default.
• W2925036534 title "Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma" @default.
• W2925036534 cites W1946476244 @default.
• W2925036534 cites W1971473979 @default.
• W2925036534 cites W2040143310 @default.
• W2925036534 cites W2099088585 @default.
• W2925036534 cites W2099752220 @default.
• W2925036534 cites W2103506609 @default.
• W2925036534 cites W2105677187 @default.
• W2925036534 cites W2117125017 @default.
• W2925036534 cites W2123784879 @default.
• W2925036534 cites W2149456801 @default.
• W2925036534 cites W2155319477 @default.
• W2925036534 cites W2161988278 @default.
• W2925036534 doi "https://doi.org/10.1177/1078155219837333" @default.
• W2925036534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30909792" @default.
• W2925036534 hasPublicationYear "2019" @default.
• W2925036534 type Work @default.
• W2925036534 sameAs 2925036534 @default.
• W2925036534 citedByCount "2" @default.
• W2925036534 countsByYear W29250365342021 @default.
• W2925036534 crossrefType "journal-article" @default.
• W2925036534 hasAuthorship W2925036534A5019396140 @default.
• W2925036534 hasAuthorship W2925036534A5039901519 @default.
• W2925036534 hasAuthorship W2925036534A5061726791 @default.
• W2925036534 hasAuthorship W2925036534A5087150696 @default.
• W2925036534 hasConcept C126322002 @default.
• W2925036534 hasConcept C141071460 @default.
• W2925036534 hasConcept C2777288759 @default.
• W2925036534 hasConcept C2777472916 @default.
• W2925036534 hasConcept C2778715236 @default.
• W2925036534 hasConcept C2779490328 @default.
• W2925036534 hasConcept C71924100 @default.
• W2925036534 hasConceptScore W2925036534C126322002 @default.
• W2925036534 hasConceptScore W2925036534C141071460 @default.
• W2925036534 hasConceptScore W2925036534C2777288759 @default.
• W2925036534 hasConceptScore W2925036534C2777472916 @default.
• W2925036534 hasConceptScore W2925036534C2778715236 @default.
• W2925036534 hasConceptScore W2925036534C2779490328 @default.
• W2925036534 hasConceptScore W2925036534C71924100 @default.
• W2925036534 hasIssue "1" @default.
• W2925036534 hasLocation W29250365341 @default.
• W2925036534 hasLocation W29250365342 @default.
• W2925036534 hasOpenAccess W2925036534 @default.
• W2925036534 hasPrimaryLocation W29250365341 @default.
• W2925036534 hasRelatedWork W2072245035 @default.
• W2925036534 hasRelatedWork W2096517981 @default.
• W2925036534 hasRelatedWork W2182272419 @default.
• W2925036534 hasRelatedWork W2480565470 @default.
• W2925036534 hasRelatedWork W2544140097 @default.
• W2925036534 hasRelatedWork W2747845777 @default.
• W2925036534 hasRelatedWork W2971476881 @default.
• W2925036534 hasRelatedWork W3151554875 @default.
• W2925036534 hasRelatedWork W4205243027 @default.
• W2925036534 hasRelatedWork W4205299447 @default.
• W2925036534 hasVolume "26" @default.
• W2925036534 isParatext "false" @default.
• W2925036534 isRetracted "false" @default.
• W2925036534 magId "2925036534" @default.
• W2925036534 workType "article" @default.